^sup 90^Y-Ibritumomab tiuxetan in the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma*

From: Journal of Nuclear Medicine Technology | Date: June 1, 2003| Author: | Copyright information

Objective: Non-Hodgkin's lymphoma (NHL) is the most frequently diagnosed malignancy of the immune system, with more than 53,900 new cases diagnosed in 2002. Conventional cancer therapies cure many, but not the majority of, cases of the aggressive forms of NHL, and the more indolent and follicular forms of the disease that affect nearly half of all patients with NHL are considered incurable. In the absence of cure or survival benefits, treatments such as radioimmunotherapy that induce remission and prolong time off therapy are considered valuable. ^sup 90^Y-Ibritumomab tiuxetan recently became ...

Read all of this article with a FREE trial to HighBeam Research

Related newspaper, magazine, and trade journal articles from HighBeam Research

(Including press releases, facts, information, and biographies)

Ibritumomab tiuxetan in NHL
; New information on the benefits of ibritumomab tiuxetan (Zevalin; IDEC Pharmaceuticals...of four previous therapies). The ibritumomab tiuxetan treatment regimen consisted of pretreatment...peripheral blood B cells, then 90Y ibritumomab tiuxetan (0.4 mCi/kg; maximum, 32 mCi) ...
Radioimmunotherapy and NHL: Nuclear medicine on the oncology team
; ...approval to Zevalin (ibritumomab tiuxetan; IDEC Pharmaceuticals...regulatory nod. 90Y-ibritumomab tiuxetan consists of a marine...or transformed B-cell NHL, including patients...or transformed B-cell NHL. The 73 patients...3.2-mg vial of ibritumomab ...
Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: From clinical trails to clinical practice
; ...sup 90^Y-ibritumomab tiuxetan anti-B-cell NHL mAb as the...sup 90^Y-ibritumomab tiuxetan, and based...radiolabeled anti-B-cell NHL mAbs, RIT...surface of B-cell NHL, whereas ibritumomab tiuxetan is the ^sup...
Radiation dosimetry results and safety correlations from (90)Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: Combined data...
; Ibritumomab tiuxetan is an anti-CD20 murine IgGi...clinical trials of ^sup 90^Y-ibritumomab tiuxetan RIT for relapsed or refractory...mm^sup 3^ for the reduced 90Y-ibritumomab tiuxetan administered dose (7.4-11 MBq...
IBRITUMOMAB TIUXETAN.(Schering AG and Idec Pharmaceuticals)(Brief Article)
; IBRITUMOMAB TIUXETAN--Schering AG and Idec Pharmaceuticals have entered into a $47...distribution rights to Idec's investigational drug, Zevalin (ibritumomab tiuxetan), formerly Idec-Y2B8, a monoclonal antibody linked to the radioisotope...
The Role of Imaging with ^sup 111^In-Ibritumomab Tiuxetan in the Ibritumomab Tiuxetan (Zevalin) Regimen: Results from a Zevalin Imaging Registry
; ...sup 111^In-ibritumomab tiuxetan, because...with the ibritumomab tiuxetan therapeutic...sup 111^In-ibritumomab tiuxetan between March...patients in whom ibritumomab tiuxetan therapy was...sup 111^In-ibritumomab tiuxetan (4.0% of...sup ...
New Data Show Zevalin(R) Highly Effective in First-Line Treatment of Low-Grade Follicular Lymphoma.
; ...ASH) demonstrated that Zevalin (ibritumomab tiuxetan), administered as a first-line therapy...disease. Delivered doses of 90Y ibritumomab tiuxetan ranged from 21-32 mCi. On day one...imaging dose of Indium 111 (111In) ibritumomab tiuxetan (5 mCi). One week later, a second...
RIT Complications and At-Risk Patients
; ...acute myelogenous leukemia (t-AML) in patients after ibritumomab tiuxetan radioimmunotherapy (RIT). The study analyzed data on t...patients with nonHodgkin's lymphoma (NHL) treated with the ibritumomab tiuxetan regimen in registration and compassionate-use trials...
Quantitative ^sup 89^Zr immuno-PET for in vivo scouting of ^sup 90Y^-labeled monoclonal antibodies in xenograft-bearing nude mice
; ...was demonstrated by, among others, ibritumomab tiuxetan (Zevalin; IDEC Pharmaceuticals...Administration, in 2002 (2). Initially, the ibritumomab tiuxetan regimen (for treating non-Hodgkin...for which the chelate-coupled mAb ibritumomab tiuxetan was labeled with 111In, followed...
First radioimmunotherapeutic for lymphomas clears FDA
; ...malignancies that attack the B and T lymphocytes of...options. Zevalin (90Y-ibritumomab tiuxetan, IDEC Pharmaceuticals...product for low-grade B-cell NHL. 90Y-ibritumomab tiuxetan is indicated for the...follicular or transformed B-cell NHL in ...